. Here we show that ME3 depletion selectively kills ME2-null PDAC cells in a manner consistent with an essential function for ME3 in ME2-null cancer cells. Mechanistically, integrated metabolomic and molecular investigation of cells deficient in mitochondrial malic enzymes revealed diminished NADPH production and consequent high levels of reactive oxygen species. These changes activate AMP activated protein kinase (AMPK), which in turn directly suppresses sterol regulatory element-binding protein 1 (SREBP1)-directed transcription of its direct targets including the BCAT2 branchedchain amino acid transaminase 2) gene. BCAT2 catalyses the transfer of the amino group from branched-chain amino acids to α-ketoglutarate (α-KG) 4 thereby regenerating glutamate, which functions in part to support de novo nucleotide synthesis. Thus, mitochondrial malic enzyme deficiency, which results in impaired NADPH production, provides a prime 'collateral lethality' therapeutic strategy for the treatment of a substantial fraction of patients diagnosed with this intractable disease.
The genome of pancreatic ductal adenocarcinoma (PDAC) frequently contains deletions of tumour suppressor gene loci, most notably SMAD4, which is homozygously deleted in nearly one-third of cases 1 . As loss of neighbouring housekeeping genes can confer collateral lethality, we sought to determine whether loss of the metabolic gene malic enzyme 2 (ME2) in the SMAD4 locus would create cancer-specific metabolic vulnerability upon targeting of its paralogous isoform ME3. The mitochondrial malic enzymes (ME2 and ME3) are oxidative decarboxylases that catalyse the conversion of malate to pyruvate and are essential for NADPH regeneration and reactive oxygen species homeostasis 2, 3 . Here we show that ME3 depletion selectively kills ME2-null PDAC cells in a manner consistent with an essential function for ME3 in ME2-null cancer cells. Mechanistically, integrated metabolomic and molecular investigation of cells deficient in mitochondrial malic enzymes revealed diminished NADPH production and consequent high levels of reactive oxygen species. These changes activate AMP activated protein kinase (AMPK), which in turn directly suppresses sterol regulatory element-binding protein 1 (SREBP1)-directed transcription of its direct targets including the BCAT2 branchedchain amino acid transaminase 2) gene. BCAT2 catalyses the transfer of the amino group from branched-chain amino acids to α-ketoglutarate (α-KG) 4 thereby regenerating glutamate, which functions in part to support de novo nucleotide synthesis. Thus, mitochondrial malic enzyme deficiency, which results in impaired NADPH production, provides a prime 'collateral lethality' therapeutic strategy for the treatment of a substantial fraction of patients diagnosed with this intractable disease.
The paucity of therapeutically actionable oncogene mutations and the frequent occurrence of tumour suppressor gene deletions in PDAC prompted us to assess cancer-specific vulnerabilities incurred by deletion of passenger genes encoding essential cellular functions. In this 'collateral lethality' framework 5 , cancer cells tolerate deletion of critical housekeeping genes owing to the co-expression of functionally redundant paralogues that maintain these essential cellular reactions 6 . Chromosomal region 18q21, which contains SMAD4, is homozygously deleted in a large fraction of human solid tumours, including PDAC 1 (Fig. 1a , Extended Data Fig. 1a, b ). This region also harbours multiple housekeeping genes including ME2, which is often deleted along with SMAD4 (Fig. 1b, Extended Data Fig. 1c-e) . Analyses of the copy number (Fig. 1c) and expression (Extended Data Fig. 1f ) of ME2 and SMAD4 show a strong positive correlation. PDAC TCGA copy-number and transcriptomic analyses (n = 185) and a study of microdissected PDAC samples (n = 109) 7 have revealed homozygous deletion of SMAD4 in 14% (25 out of 185) and 29% (32 out of 109) of tumours, respectively, with ME2 deletion in 64% (16 out of 25, homozygous deletion) and 96% (31 out of 32, homozygous deletion) of these SMAD4-deleted cases, respectively (Fig. 1d , e, Extended Data Fig. 1g ). 
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Exclusion of stromal content in the microdissection study is likely to account for the higher codeletion of SMAD4 and ME2 in this study. Furthermore, immunohistochemistry (IHC) analysis of ME2 and SMAD4 expression in 62 PDAC and 77 matched normal samples revealed corresponding loss of both proteins in 37% of PDAC cases (Extended Data Fig. 1h-k) . Beyond PDAC, homozygous deletion of ME2 occurs in many other cancers (Fig. 1e) .
The family of malic enzymes consists of three isoforms: a cytosolic NADP + -dependent isoform (ME1) and two redundant mitochondrial NAD(P) + -dependent isoforms (ME2 and ME3) 2, 3 . In normal cells and most cancer cells, ME2 is the main isoform in mitochondria and has higher abundance and enzymatic activity compared to ME3 (ref. 3) . However, in the absence of ME2, ME3 presumably sustains essential NADPH synthesis in mitochondria.
To test the hypothesis that ME3 enables survival of ME2-deficient cells, we identified 12 lines with homozygous deletion of ME2 from the 46 PDAC cell lines in the Cancer Cell Line Encyclopedia (CCLE) database (Fig. 1a) . We validated and used four ME2 homozygous null (hereafter ME2-null) (Panc05.04, Hs766T, PATU8988T, BxPC3) and five ME2-intact (PATU8902, ASPC1, KP-1NL, PK59, Panc1) cell lines (Fig. 2a, b) . Consistent with the cell-essential and redundant function of malic enzymes in mitochondria, we observed a compensatory increase in ME3 expression in ME2-null cell lines (Fig. 2b) . Similar observations were made in matched normal and PDAC samples, which showed an increase in ME3 expression (59%, 37 out of 62), and in the CCLE database, where there is a gain at the ME3 locus (65%, 30 out of 46) (Extended Data Fig. 2a-c) . Overall, these findings suggest that mitochondrial malic enzymes have redundant and cell-essential roles, prompting us to hypothesize that collateral lethality would result from depletion of ME3 in ME2-null PDAC cells.
We surmised that ME1 might not be a viable collateral lethality target, as ME1 is expressed solely in the cytosolic compartment and is essential for biosynthetic pathways such as fatty acid biosynthesis, supplying NADPH to both cancer and normal cells. Indeed, ME1 proved to be essential for the survival of both PDAC cells and normal fibroblasts, as evidenced by increased cell death upon either short hairpin (sh) RNA or doxycycline (dox)-inducible short hairpin (ish)RNA-mediated knockdown of ME1 in both ME2-null (PATU8988T) and ME2-intact (KP-1NL, NHDF-Neo) cell lines (Extended Data Fig. 2d-l) .
We tested the effect of ME3 depletion as a collateral lethal target in the ME2-null context using dox-inducible shRNA in ME2-null and ME2-intact cells. Specifically, dox-induction of ME3 shRNA decreased colony formation and proliferation (Fig. 2c, d , Extended Data Fig. 3a-m) and profoundly impaired tumour growth and increased survival in subcutaneous and orthotopic models of ME2-null PDAC tumours (Fig. 2e , f, Extended Data Fig. 3n-r) . Inhibition of tumour growth was accompanied by significantly reduced cell proliferation and increased cell death (Extended Data Fig. 4a, b) , which was consistent with the identification of enriched cell proliferation and cell death pathways by RNA sequencing (RNA-seq) and Ingenuity Pathway Analysis (Extended Data Fig. 4c, d ). Moreover, in vitro apoptosis assays of ME3-depleted cells showed increased annexin V-positive cells when compared with control cells (Extended Data Fig. 5a, b) . Finally, these anti-tumour phenotypes were alleviated by ectopic expression of ME2 in mitochondrial ME3-depleted cells (Fig. 2g , Extended Data Fig. 5c-g ), thus establishing that the paralogous ME3 isoform has a compensatory function in ME2-deleted PDAC cells.
Given the observed alterations in PGC1α and TCA cycle expression signatures (Extended Data Fig. 5h, i) following ME3 depletion in ME2-null PDAC cells, and the established function of malic enzymes in mitochondrial redox balance, we sought to confirm the role of malic enzymes in the maintenance of mitochondrial redox homeostasis in PDAC. We therefore treated ME3-depleted and non-depleted control cells with cell-permeable reduced glutathione (GSH) or antioxidant N-acetylcysteine (NAC). Treatment with either GSH or NAC resulted in partial rescue in colony-formation assays, consistent with a function for mitochondrial malic enzymes in redox homeostasis. (Extended Data Fig. 5j ), but the partial rescue belied additional non-redox functions of mitochondrial malic enzymes (see below). Indeed, consistent with the role of malic enzymes in converting malate to pyruvate, the addition of 5 mM cell-permeable pyruvate decreased ROS and moderately rescued colony formation (Extended Data Fig. 5k-n) .
Mitochondrial malic enzymes are required for maintaining the NADPH pool, matching mitochondrial demand for reducing Letter reSeArCH equivalents to detoxify mitochondrial reactive oxygen species (ROS) 8 . In addition to the pyruvate study above, we also assessed the utilization of metabolites, especially glucose (Glc) and glutamine (Gln). We have shown previously that Glc and Gln are essential for PDAC cell survival [9] [10] and are key suppliers of TCA cycle intermediates. Metabolic analyses showed that ME3 depletion in ME2-null cells led to an increase in Gln flux via the TCA cycle, as indicated by metabolite isotopomer tracing of ME3-depleted cells using uniformly 13 C-labelled Gln ([U- 13 C 5 ]Gln) as a tracer (Extended Data Fig. 5o , p). The increase in Gln flux via the TCA cycle induced by ME3 depletion indicates that metabolic re-wiring compensates for mitochondrial stress by using an alternate pathway (Gln) to replenish NADPH. Glc flux to lactate and pyruvate was unchanged following ME3 depletion in ME2-null cells, but Glc entry into the TCA cycle was decreased upon depletion of mitochondrial malic enzymes (Extended Data  Fig. 6a, b) . Similarly, Glc uptake and lactate secretion rates remained unchanged upon ME3 depletion in both ME2-null (Extended Data Fig. 6c-f ) and ME2-intact cells (Extended Data Fig. 6l-o) . Further functional analysis using Seahorse revealed that depletion of mitochondrial malic enzymes decreased oxygen consumption rate (OCR) compared with ME3 non-depleted controls (Extended Data Fig. 6g) . Conversely, the extracellular acidification rate (ECAR), an indirect measurement of glycolysis, was unchanged upon depletion of mitochondrial malic enzymes (Extended Data Fig. 6h) . Similarly, we found no change in OCR and ECAR in ME2-intact KP-1NL cells (Extended Data Fig. 6i, j) . These data suggest that ME3 depletion leads to inhibition of mitochondrial function. To further validate the effect of ME3 depletion on mitochondrial function, we stained the cells with MitoTracker red, a marker of mitochondrial structure. ME3 depletion in ME2-null cells generated profound changes in mitochondrial structure, resulting in a more globular appearance as seen by MitoTracker red staining (Fig. 3a, Extended Data Fig. 6k ). In addition, ME3-depleted cells stained intensely for MitoTracker green, an indicator of mitochondrial biomass (Extended Data Fig. 6p , q). These data were reinforced by transmission electron microscopy (TEM) showing aberrant ring-shaped mitochondria, a feature consistent with ROSmediated stress (Fig. 3b ).
As our previous work established that Gln is required for maintenance of redox homeostasis and ultimately for PDAC cell survival 11 , we sought further to explore the molecular mechanism that leads to mitochondrial dysfunction and ultimately cell death upon ME3 depletion.
To that end, we analysed the utilization of amino acids by ME3-depleted cells. We did not observe a change in Gln uptake in either ME3-depleted ME2-null (PATU8988T) or ME3-depleted ME2-intact (KP-1NL) cells by ultra-performance liquid chromatography (UPLC) analysis (Extended Data Fig. 7a, b) . However, we observed a substantial decrease in uptake of branched-chain amino acids (BCAAs; isoleucine, leucine and valine) upon ME3 depletion in ME2-null cells but not in ME2-intact cells (Fig. 3c, d , Extended Data Fig. 7c, d ). BCAAs are important contributors of amino groups to α-KG in the synthesis of glutamic acid (Glu) 12 (Extended Data Fig. 8a ). Muscles act as an immediate repository of BCAAs, which constitute more than 50% of the amino acid uptake from the circulation 13, 14 . An increase in BCAAs in the circulation is an indication of high protein turnover and muscle breakdown, which are hallmarks of cancer cachexia seen in many patients with PDAC 15 . Furthermore, BCAA derived from muscle breakdown provides a continuous source of Gln. Collectively, these observations prompted speculation that these systemic metabolic shifts may support PDAC genesis and progression by supplying BCAAs [16] [17] [18] . Upon ME3 depletion in ME2-null cells, RNA-seq, immunoblot and IHC ( Fig. 3e -g, Extended Data Fig. 8b-f ) analyses showed substantial downregulation of BCAT2. BCAT2 is a mitochondrial isoform 4, 19 required for the first step in BCAA catabolism, where the amino group of BCAAs is transferred to α-KG to generate Glu (Extended Data Fig. 8a) . Notably, the exocrine pancreas has one of the highest BCAT2 activity of all tissues 19 . BCAT2 operates at near equilibrium in most cells, and a small change in its availability can greatly affect BCAA catabolism owing to a decrease in mitochondrial BCAA uptake leading to BCAA accumulation inside the cytosol of ME3-depleted cells 13, 20, 21 (Fig. 3h) . Next, we sought to elucidate the basis of BCAT2 downregulation. We predicted and confirmed that ME3 depletion in ME2-null cells (but not ME2-intact cells) would result in ROS accumulation, correlating with a reduction in NADPH and reduced Letter reSeArCH glutathione (Fig. 3i-o and Extended Data Fig. 8g-i ), which aligned with increased expression of the antioxidant protein regulator NRF2 (Extended Data Fig. 8j, k) . Correspondingly, ME2 overexpression restored NADPH levels and decreased ROS (Extended Data Fig. 9a, b) . High intracellular ROS is known to induce AMPK 22 , an established indicator of metabolic stress. AMPK activation (evidenced by phosphorylation of Thr172) 23 was observed upon ME3 depletion (Fig. 4a ). Transient expression of kinase-dead AMPK (T172A) largely abolished the effect of ME3 depletion on BCAT2 expression (Fig. 4b) . Moreover, ME2 overexpression rescued BCAT2 expression in ME3-depleted cells (Fig. 4c) . Similarly, the anti-oxidants EUK134 (Fig. 4d) and TROLOX (Extended Data Fig. 9c ) restored BCAT2 expression. Conversely, pharmacological activation of AMPK using the cellpermeable AMPK activator AICAR led to downregulation of BCAT2 (Extended Data Fig. 9d ). Together, these findings demonstrate that elevated ROS activates AMPK, which in turn suppresses BCAT2 expression.
On the mechanistic level, a binding site in the BCAT2 promoter was identified and confirmed for SREBP1c, a known target regulated by AMPK (Fig. 4e) . Activated AMPK inhibits SREBP1 activity 24 . SREBP1 is a sterol-sensing transcription factor that promotes lipogenesis. Activation of SREBP1 by mTORC1 leads to nuclear translocation of SREBP1 and subsequent transcription of its target genes 25 , such as the genes encoding acetyl CoA carboxylase (ACC) and fatty acid synthase (FAS). Thus, AMPK inhibits nuclear translocation of SREBP1 by phosphorylation and thereby suppresses its target genes 24 . Indeed, depletion of ME3 in ME2-null cells increased SREBP1 phosphorylation (Fig. 4f) . Moreover, shRNA-mediated depletion of SREBP1 or BCAT2 (Fig. 4g) , both of which decreased BCAT2 expression, led to a comparable decline in colony formation (Fig. 4h, Extended Data Fig. 9e ). Transient expression of a dominant-negative SREBP1c 26 , which disrupts the binding of SREBP1c to the sterol response element (SRE), decreased expression of BCAT2, ACC and FAS (Fig. 4i) . In addition, BCAT2 overexpression in ME3-depleted cells (PATU8988T-ishME3) Letter reSeArCH led to aggressive tumour growth, suggesting that PDAC tumours are acutely dependent on BCAAs (Fig. 4j) . However, the impact of BCAT2 levels appears to be independent of mitochondrial respiration, as neither BCAT2 knockdown nor overexpression was observed to alter the OCR (Extended Data Fig. 9f, g ).
ME3 depletion in ME2-null cells inhibited amino group transfer from BCAA to α-KG; this effect is reminiscent of BCAT2 knockdown, as shown by 15 N-labelled BCAA ( 15 N-Leu) tracing (M1 Glu) (Extended Data Fig. 10a) . A similar decrease in amino group transfer to synthesize alanine (Ala) and serine (Ser) (non-essential amino acids derived from Glu) was also observed (Extended Data Fig. 10b, c) . However, 13 C-labelled BCAA flux analysis did not detect changes in TCA cycle flux (Extended Data Fig. 10d) . It is known that Gln contributes its amino group to synthesize ammonia required for the de novo synthesis of nucleotides, especially pyrimidine 27 . Notably, addition of a mixture of nucleotides (adenine, guanine, cytosine, thymine and inosine) rescued colony formation after ME3 depletion in ME2-null cells, indicating that BCAA-derived nucleotide precursors are rate limiting to cell viability (Fig. 4k, Extended Data Fig. 10e ). In summary, these findings are consistent with multiple consequences of mitochondrial malic enzyme depletion, including (i) ROS-mediated activation of the AMPK pathway causing a decrease in BCAA breakdown and thereby leading to a decrease in de novo nucleotide biosynthesis, and (ii) ROSmediated mitochondrial damage leading to activation of apoptotic pathways (Fig. 4l) . Overall, our study provides a mechanistic basis for the loss of cancer cell viability upon depletion of mitochondrial malic enzymes.
Here, in an effort to expand therapeutic strategies beyond oncogenic targets to those not directly linked to cancer pathogenesis, we have identified a collateral lethal vulnerability in PDAC that can be targeted pharmacologically in genotype-defined patient populations. Genomic data across many cancers further suggest that this therapeutic strategy may be effective for many patients, including those suffering from gastric and colon cancers. Our work also suggests a mechanism for cell lethality involving the regulation of BCAAs as crucial metabolites in PDAC, under the critical regulation of the mitochondrial malic enzymes. We propose that highly specific ME3 inhibitors could provide an effective therapy for a meaningful fraction of cancer patients.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Cell culture. All the cell lines used in this study were purchased from ATCC, used below passage 25 and continuously cultured in 100 U/ml penicillin and 100 U/ml streptomycin. The cell lines were authenticated by short tandem repeat (STR) profiling at the Institute for Applied Cancer Sciences, MD Anderson Cancer Center. The PATU8988T, Hs766T and PATU8902 cell lines were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) (Invitrogen). AsPc1, BxPC3 and KP-1NL cell lines were routinely cultured in Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen) with 10% FBS, and Panc05.04 cells were routinely cultured in RPMI 1640 with 15% FBS. For metabolic and metabolomic assays, 10% dialysed FBS (Atlanta Biologicals Inc.) was used. For BCAA experiments, DMEM medium without BCAAs was used (United States Biological). NHDF-neo-fibroblasts were cultured in Eagle's modified medium (EMEM) with 10% FBS. The cell lines were mycoplasma free, based on tests done monthly in the laboratory using Lonza's MycoAlert Mycoplasma Detection Kit assays with confirmatory tests by PCR-based assays. Reagents and chemicals. Trolox (Cat. No. 238813) and AICAR (A9978) were purchased from Sigma. EUK134 (Cat. No. 10006329) was purchased from Cayman Chemicals. 13 C-and 15 N-labelled isotopes were purchased from Cambridge Isotope Laboratories. siRNA, shRNA and CRISPR knockdown. shRNA knockdown was performed essentially as described previously 6 . We screened five hairpins targeting ME3 and found three independent sequences that reduced mRNA levels by >60%. Initial hairpin screenings were performed in the pLKO.1 shRNA vectors (Sigma Aldrich), while actual experiments were performed in the doxycycline-inducible pLKO.1 ishRNA vectors (engineered in the laboratory) using the sequences from the pLKO.1 screening (ME1, ME2 and ME3 only). The ME3 ishRNA sequences were as follows: i sh ME 3#1 ( CC GG GC TC AA CA AA TA CC GT AA CA AC TC GA GT TG TT AC GG TATTTGTTGAGCTTTTTG), ishME3#2 (CCGGCGTGTCTTTGAGAATTGCCATCTCGAGATGGC AATTCTCAAAGACACGTTTTTG) and ishME3#3 (CCGGCCTCCGA ATCATGAGATATTACTCGAGTAATATCTCATGATTCGGAGGTTTTTG). The ME1 shRNA sequences were as follows: ishME1#3 (CCGGGCTGAGGTTA TAGCTCAGCAACTCGAGTTGCTGAGCTATAACCTCAGCTTTTTG) and ishME1#5 (CCGGCCTGTGGGTAAATTGGCTCTACTCGAGTAGAG CCAATTTACCCACAGGTTTTTG). The SREBP1 shRNA sequences were as follows: shSREBP1#2 (CCGGGCCATCGACTACATTCGCTTTCTCGAGA AAGCGAATGTAGTCGATGGCTTTTT) and shSREBP1#3(CCGGGCTG AATAAATCTGCTGTCTTCTCGAGAAGACAGCAGATTTATTCAGCTTTTT). The BCAT2 shRNA sequences were as follows: shBCAT2#2 (CCGGTGA AGTGCAATACGAAATAAACTCGAGTTTATTTCGTATTGCACTTCATTT TTG) and shBCAT2#3 (CCGGGT G CA CCGAATCCTGTACAAACTCGAGT TTGTACAGGATTCGGTGCACTTTTTG). A non-targeting shRNA (shCtrl) was used as a control. The shRNA-expressing pLKO.1 vector was introduced into cancer cell lines by lentiviral infection. Recombinant lentiviral particles were produced by transient transfection of 293T cells following a standard protocol. Briefly, 10 μg of the shRNA plasmid, 5 μg of psPAX2 and 2.5 μg of pMD2.G were transfected using polyethylenimine (1 μg/μl, Polysciences # 23966-2) into 293T cells plated in a 100-mm dish. Viral supernatant was collected 72 h after transfection, centrifuged to remove any 293T cells and filtered (0.45 μm). For transduction, viral solutions were added to cell culture medium containing 4 μg/ml polybrene; 48 h after infection, cells were selected using 2 μg/ml puromycin and tested for ME1 and ME3 depletion by qRT-PCR or immunoblotting. siRNA targeting ME3 (Accell SMARTpool) was purchased from Dharmacon and used according to the manufacturer's protocol. For CRISPR knockdown of ME2, sgRNA were designed based on the recommendations from ref. 28 (http://portals.broadinstitute.org/ gpp/public/analysis-tools/sgrna-design-v1). The sgRNA were then cloned into pL-CRISPR.EFS.GFP (Addgene#357818) 29 . The sgRNA sequences are sghME2-A_ sense: CACCGCCAATTGTATATACACCGA; sghME2-A_antisense: AAACT CGGTGTATATACAATTGGC; sghME2-B_sense_F:CACCGAGCAGGCAAGAC CAACCGT; sghME2-B_antisense:AAACACGGTTGGTCTTGCCTGCTC. For inducible CRISPR knockdown of ME3 the following plasmids were obtained from TranOMICS Technologies: three independent ME3 gRNA clones (pCLIP-gRNA-EFS-Blast and pCLIP-gRNA-EFS-ZsGreen), Cas9-Nickase-Puro and pTOL-tetR vectors. The plasmids were virally transduced into cell lines in sequence and the cells were selected for single clones at every step. MitoTracker analysis. Cells for the assay were grown on or off doxycycline in 100-mm dishes for 72 h. Twenty-thousand cells per 96 well were seeded for the flow cytometry and microplate spectrophotometry-based assay. On the next day, the medium was removed, and pre-warmed (37 °C) staining solution containing 50 nM MitoTracker probes was added and incubated for 45 min at 37 °C. After staining was completed, the staining solution was replaced with Immunohistochemistry and immunofluorescence. Tissues were fixed in 10% formalin overnight and embedded in paraffin. IHC was performed as described previously 30 . Briefly, endogenous peroxidases were inactivated by 3% hydrogen peroxide. Non-specific signals were blocked using 3% BSA, 10% goat serum in 0.1% Triton X-100. Tumour samples were stained with the following primary antibodies: ME2 (Santa Cruz, sc-85051; Sigma Prestige, HPA008247), ME3 (Sigma Prestige, HPA038473), SMAD4 (Santa Cruz, sc-7966), BCAT2 (Abcam, ab197917), Ki67 (Vector Laboratory, VP-RM04) and cleaved caspase 3 (CST, 9661). After overnight incubation, the slides were washed and incubated with secondary antibody (HRPpolymers, Biocare Medical) for 30 min at room temperature. The slides were washed three times and stained with DAB substrate (ThermoFisher Scientific). The slides were then counterstained with haematoxylin and mounted with mounting medium. Human PDAC primary tumour samples. PDAC samples were obtained from MD Anderson Cancer Center's tissue Biobank. The samples were stained using the standard IHC protocol. The antibodies used were ME2 (Sigma Prestige, HPA008247) and ME3 (Sigma Prestige, HPA038473). SMAD4 (Santa Cruz, sc-7966) antibody staining was conducted using a CLIA-certified protocol and reagents. The stained samples were imaged using Pannoramic 250 slide scanner and data analysed using Pannoramic viewer software (3DHISTECH Ltd) by two independent pathologists. Human studies were approved by The UT MD Anderson Cancer Center's institutional review board (IRB protocol number: LAB05-0854) and informed consent was obtained from all subjects. Chromatin immunoprecipitation. ChIP was performed as described previously 31 using SREBP1 antibody (Santa Cruz, sc-367x). Briefly, 5 μg rabbit IgG (Santa Cruz) or SREBP1 antibody was incubated with Protein A Dynabead magnetic beads (Invitrogen) for 4 h, followed by extensive washing to remove unbound antibody. Antibody beads were then added to the chromatin and incubated overnight. The ChIP primers were purchased from Qiagen (EpiTect ChIP PCR assay) and used for qPCR analysis: BCAT2 (GPH1020848(+)03A). Transcriptomic profiling by RNA-seq and qRT-PCR. RNA was isolated from tumour tissues using Trizol extraction followed by purification with the Qiagen RNAeasy kit as described previously 32, 33 . RNA-seq was performed by the Sequencing and Microarray Facility (SMF) core at MD Anderson. Libraries were generated using Illumina's TruSeq kit and were sequenced using the Illumina HiSeq2000 Sequencer. Raw read RNA-seq data were mapped to the hg19 reference genome using Bowtie 34 . The mapped reads were then assembled by Cufflinks 35 to generate a transcriptome assembly for each sample. After the assembly phase, Cufflinks quantified the expression of the transcriptome in each gene for each sample (that is, FPKM, fragments per kilobase of transcript per million fragments mapped). For qRT-PCR, RNA samples were reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcript kit (Life Technologies). cDNA samples were subjected to qRT-PCR quantification in duplicate and performed with Power SYBR Green PCR Master Mix (Invitrogen) according to the product guides on a Agilent Mx3005P and Applied Biosystems AB7500 Fast Real Time machine.
The primer sequences used for real-time qRT-PCR are the following: ME2 (Fwd 5′ ATTAGTGACAGTGTTTTCCTA 3′, Rev 5′ CTATTCTGTTATCACAGG 3′), BCAT2 (Fwd 5′ CTCTGGGGCAGCTGTTTGA 3′, Rev 5′ ATAACACCAT TCAGCGGGGG 3′). Stable isotope analysis using GC-MS: metabolite extraction. Cells were cultured in 6-well plates overnight and treated the next day with doxycycline for 72 h. Cells were then cultured in the presence of carbon-or nitrogen-labelled isotope tracers for 24 h. The medium was removed and cells were washed with ice-cold PBS solution. Next, cells were quenched with 400 μl methanol and 400 μl water containing 1 μl norvaline, scraped, washed with 800 μl ice-cold chloroform, vortexed at 4 °C for 30 min and centrifuged at 7,300 r.p.m. for 10 min at 4 °C. The upper aqueous phase was collected for metabolite analysis. Derivatization. Samples were first dried using a Speedvac, followed by the addition of 30 μl of 2% methoxyamine hydrochloride in pyridine (Pierce) and sonication for 15 min. Samples were then kept at 37 °C for 2 h, then at 55 °C for 1 h following the addition of 45 μl MBTSTFA + 1% TBDMCS (Pierce). Samples were next transferred to vials equipped with inserts. GC-MS measurements. Metabolites were analysed using an Agilent 6890 GC equipped with a 30-m Rtx-5 capillary column connected to an Agilent 5975B MS operating under electron impact ionization at 70 eV. Samples were injected at 1 μl and 270 °C in splitless mode, and helium was used as the carrier gas at 1 ml/min. The heating cycle for the GC oven was as follows: 100 °C for 3 min, followed by 300 °C at 5 °C/min temperature increase, for a total run time of 48 min per sample. Data were acquired in scan mode and the integrated signal of all potentially labelled ions was normalized by the norvaline signal and used to calculate the abundance of relative metabolites. The mass isotopomer distribution was obtained by dividing the signal of each isotopomer by the sum of all isotopomer signals, corrected for natural abundance. Oxygen consumption and glycolytic capacity. PDAC cells (PATU8988T and KP-1NL) were plated into XF Cell Culture Microplates (Seahorse Bioscience) overnight at 37 °C and 5% CO 2 . The next day, cells were treated with doxycycline for 72 h. To measure OCR and ECAR, media were replaced in the Seahorse microplates with assay medium free of sodium bicarbonate and FBS, and the plate was incubated in a CO 2 -free incubator for 1 h at 37 °C. Oligomycin, FCCP, and rotenone were sequentially injected at a final concentration of 2 μg/ml, 1 μM and 1 μM, respectively. Experiments were run using an XF analyser and raw data were normalized with total protein measured in each well of the microplate. Glucose uptake and lactate production. Glucose uptake and lactate secretion were measured using Wako Glucose kit and Trinity Lactate kit, respectively. Briefly, 200 μl of reconstituted Wako glucose reagent or lactate reagent were added to a 96-well plate and mixed with 10-μl samples that were diluted 1:10 in PBS. To measure glucose uptake, the plate was incubated for 15 min at 37 °C, and the change in absorbance was recorded using a spectrophotometer (SpectraMax M5, Molecular Devices) at 505 nm. For lactate measurement, the plate was incubated for 1 h at 37 °C and absorbance was read at 540 nm. Raw data were normalized to total protein per well. Amino acid uptake. Amino acid uptake and secretion rates were measured using UPLC (Waters Acquity). Briefly, cells were seeded in 12-well plates and treated for 72 h with doxycycline. Spent media were collected, deproteinized and mixed with MassTrak Reagent and Borate Buffer/NaOH. Samples were heated at 55 °C for 10 min and analysed using the Water ACI UPLC system. Instrument eluents were prepared according to protocol and eluents were run at 0.4 ml/min with UV detection set at 260 nm.
Pyruvate and nucleotide rescue experiments. For the pyruvate rescue experiment, 5 mM sodium pyruvate or methyl pyruvate were added to DMEM with 10% Tet-free FBS. The medium also lacked glucose and glutamine, and was supplemented with 25 mM glucose and 2 mM glutamine wherever required. For the nucleotide experiment, 250 μM nucleotide mixture (adenine, guanine, cytosine, thymine and inosine) was supplemented directly into complete DMEM with 10% Tet-free FBS. Chromogenic spectrophotometric NADPH assay. NADPH was measured using the NADP/NADPH assay kit (Abcam) following the manufacturer's protocol. Briefly, 4 × 10 6 cells were harvested in cold PBS and extracted using extraction buffer by two freeze-thaw cycles (20 min on dry ice followed by 10 min at room temperature). The samples were vortexed and centrifuged at 14,000 r.p.m. for 5 min. The extracted samples were centrifuged at 14,000 r.p.m. and the supernatant transferred to a new tube. NADP/NADPH inhibiting enzymes were removed using 10 kD Spin Column (Abcam, ab93349). NADPH and total NADP were measured upon decomposition of NADP by heating at 65 °C. Multiple readings were taken at OD 450 followed by calculation of total NADP and NADPH. Malic enzyme activity assay. Malic enzyme activity was quantified in native, non-denatured lysates of cancer cell lines following the method of Orsomando et al. 36 , with slight modifications. Native lysates were prepared with 20 mM Tris (pH 7.4), 1 mM EDTA and 1 mM β-mercaptoethanol 6 . After scraping, cells were broken by sonication and lysates cleared by centrifugation at 15,000 r.p.m. for 15 min. Protein concentration was determined and normalized across samples. The reference assay mixture (0.4 ml final volume) contained 100 mM triethanolamine (pH 7.5), 25 mM MgCl 2 , 20 mM NaF, 1 mM both NMN and ATP, and 100 μg of cell lysate. In this assay, malate and NADP are converted to NADPH, which was left to run for 30 min; after this incubation, the assay was stopped and NAD + was measured using the spectrophotometric chromogenic assay described in the section above. Controls included samples with lysis buffer only and reaction buffer (which omits malate). Subcutaneous and orthotopic tumour formation. All animal procedures were approved by the MD Anderson Animal Care and Use Committee (IACUC Protocol number 00001039). Subcutaneous tumours were established by injection of 500,000 cells into the flanks of immune-compromised male mice (Taconic), aged 4-6 weeks. These experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment. No statistical method was used to predetermine sample size. The animal sizes for the study were estimated based on previous experience using similar mouse models that showed significance. Animals were killed for humane reasons when tumours were ~15 mm in diameter. Doxycycline was provided to the animals as indicated in the form of dox water (dox 2 mg/ml, sucrose 40 mg/ml) starting 2 days after transplantation. For late induction of ME3 ishRNA, dox water was started 32 days after transplantation. For orthotopic pancreas transplantation, nude mice were anaesthetized using ketamine/xylazine. An incision was made in the left abdomen and the pancreas was gently pulled out along with the spleen. Luciferase-expressing cells were slowly injected into the tail of the pancreas using a Hamilton syringe. 5 μl cells (5 × 10 5 ) mixed with 5 μl Matrigel were injected. For the orthotopic model, animals were imaged (IVIS Spectrum, PerkinElmer) 2 days after surgery to assess successful implantation of the tumours. Only orthotopic tumours of similar luciferase intensity were used further for the study. These criteria were pre-established. Furthermore, the animals were luciferase imaged to monitor the progress of the tumour at different time points. Dox water treatment was started 2 days after transplantation. Measurement of total and mitochondrial ROS. A DCFDA cellular ROS detection assay (ThermoFisher Scientific) was used to measure total ROS activity within the cells. A total of 2.5 × 10 4 cells per well were seeded on a 96-well plate and allowed to attach overnight. The cells were then stained with 25 μM DCFDA for 45 min at 37 °C. After staining, the cells were washed and measured using flow cytometry. 100 μM tert-butyl hydroperoxide (TBHP) was used as a positive control. For measurement of mitochondrial ROS, MitoSOX red mitochondrial superoxide (ThermoFisher Scientific, M36008) was used according to the manufacturer's protocol. In brief, a total of 2.5 × 10 4 cells per well was seeded on a 96-well plate and allowed to attach overnight. The cells were then stained with 5 μM MitoSOX for 10 min at 37 °C. After staining, the cells were washed and measured using flow cytometry. Transmission electron microscopy (TEM). TEM was performed at MD Anderson's High Resolution Electron Microscopy Facility. Samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3) for 1 h. After fixation, the samples were washed and treated with 0.1% Millipore-filtered cacodylate buffered tannic acid, postfixed with 1% buffered osmium tetroxide for 30 min, and stained en bloc with 1%
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Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated and embedded in LX-112 medium. The samples were polymerized in a 60 °C oven for 2 days. Ultrathin sections were cut in a Leica Ultracut microtome, stained with uranyl acetate and lead citrate in a Leica EM Stainer and examined in a JEM 1010 transmission electron microscope (JEOL, USA, Inc.) at an accelerating voltage of 80 kV. Digital images were obtained using an AMT Imaging System (Advanced Microscopy Techniques Corp). Statistical analysis. Graphpad Prism software was used to conduct the statistical analysis of all data, except for qRT-PCR, stable isotope tracing, amino acids utilization and Seahorse data where Microsoft Excel was used. Data are presented as mean ± s.d. except for metabolic and metabolomic experiments where data are presented as mean ± s.e.m. All quantitative results were assessed by unpaired Student's t-test after confirming that the data met appropriate assumptions (normality and independent sampling). The Student's t-test assumed two-tailed distributions to calculate statistical significance between groups. Unless otherwise indicated, for all in vitro experiments, three technical replicates were analysed. Sample size estimation was done taking into consideration previous experience with animal strains, assay sensitivity and tissue collection methodology used. For mouse and clinical studies, the staining intensity of tissue sections was scored in a 'blinded' manner by two independent pathologists. Animal survival benefit was determined by Kaplan-Meier analysis. P < 0.05 was considered statistically significant and the P value is indicated in the figures.
Data availability. The RNA-seq data have been submitted to the Gene Expression Omnibus under accession number GSE80411. All other raw data generated or analysed during this study are included in this published article (and its Supplementary Information files). RNA-seq data showing enrichment of TCA cycle signature. j, Colonyformation data for PATU8988T-ishME3 cells rescued with GSH (4 mM) or NAC (4 mM). k, Expression of pAMPK1-T172, BCAT2 and ME3 upon treatment with Glc (10 mM), Gln (2 mM) and/or Pyr (5 mM). l, Raw flow cytometric plot of DCFDA upon rescue with pyruvate (5 mM). m, Relative DCFDA fluorescence upon rescue with pyruvate. n, Colony-formation data for PATU8988T-ishME3 cells rescued with pyruvate (5 mM). o, Mapping of carbon atom transitions using uniformly labelled 13 C 5 -glutamine. p, Mass isotopomer distribution (MID) of uniformly labelled 13 C 5 -glutamine contribution to TCA cycle metabolites. ME3 depletion led to increased glutamine flux into TCA cycle. Error bars represent s.e.m. of n = 4 biological samples from two independent experiments. P values were determined by two-tailed t-test. 
